PL1942932T3 - Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek - Google Patents

Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek

Info

Publication number
PL1942932T3
PL1942932T3 PL06851676T PL06851676T PL1942932T3 PL 1942932 T3 PL1942932 T3 PL 1942932T3 PL 06851676 T PL06851676 T PL 06851676T PL 06851676 T PL06851676 T PL 06851676T PL 1942932 T3 PL1942932 T3 PL 1942932T3
Authority
PL
Poland
Prior art keywords
hydrogen peroxide
vaccine production
inactivating pathogens
inactivating
pathogens
Prior art date
Application number
PL06851676T
Other languages
English (en)
Inventor
Mark K Slifka
Shirley W Villadiego
Erika Hammarlund
Paul Yoshihara
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Publication of PL1942932T3 publication Critical patent/PL1942932T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24061—Methods of inactivation or attenuation
    • C12N2710/24063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C12N2710/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10061—Methods of inactivation or attenuation
    • C12N2760/10063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL06851676T 2005-08-08 2006-08-07 Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek PL1942932T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70655505P 2005-08-08 2005-08-08
EP06851676.4A EP1942932B1 (en) 2005-08-08 2006-08-07 Inactivating pathogens with hydrogen peroxide for vaccine production
PCT/US2006/030786 WO2008039171A2 (en) 2005-08-08 2006-08-07 Inactivating pathogens with hydrogen peroxide for vaccine production

Publications (1)

Publication Number Publication Date
PL1942932T3 true PL1942932T3 (pl) 2013-11-29

Family

ID=39167699

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06851676T PL1942932T3 (pl) 2005-08-08 2006-08-07 Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek

Country Status (6)

Country Link
US (3) US8124397B2 (pl)
EP (1) EP1942932B1 (pl)
CA (1) CA2618306C (pl)
ES (1) ES2423663T3 (pl)
PL (1) PL1942932T3 (pl)
WO (1) WO2008039171A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2423663T3 (es) 2005-08-08 2013-09-23 Oregon Health And Science University Inactivación de patógenos con peróxido de hidrógeno para la producción de vacunas
US8402065B2 (en) * 2008-01-24 2013-03-19 Oracle International Corporation Electronic control batch record
US8234248B2 (en) * 2008-01-24 2012-07-31 Oracle International Corporation Tracking changes to a business object
CN102202688B (zh) * 2008-11-07 2017-04-12 印度血清研究所私人有限公司 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法
SG2014014385A (en) 2009-02-17 2014-04-28 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2973863C (en) 2009-07-31 2022-05-17 Ge Healthcare Bio-Sciences Corp. High yield yellow fever virus strain with increased propagation in cells
CN102648003B (zh) * 2009-10-09 2016-01-13 儿童医疗中心有限公司 选择性裂解的全细胞疫苗
BR112012028146A2 (pt) * 2010-05-06 2015-09-15 Novartis Ag compostos de peróxido orgânico para inativação de microorganismos
US20140335115A1 (en) * 2013-05-07 2014-11-13 Oregon Health & Science University Suppressors of mature t cells
EP3158061B1 (en) 2014-06-20 2019-08-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/dengue viruses and methods of use
WO2016131459A2 (de) 2015-02-19 2016-08-25 Paul Schaffrath Verfahren zur inaktivierung von krankheitserregern mit elektrisch erzeugten silberionen
DE102015208801A1 (de) 2015-05-12 2016-11-17 Paul Schaffrath Verfahren zur Inaktivierung von Krankheitserregern mit elektrisch erzeugten Silberionen
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
EP3408281A4 (en) 2016-01-29 2019-08-14 Advanced Animal Diagnostics, Inc. METHOD AND COMPOSITIONS FOR DETECTING MYCOPLASMA EXPOSURE
US20170276663A1 (en) 2016-03-22 2017-09-28 Advanced Animal Diagnotics, Inc. Methods and compositions for reducing antibiotic administration to farm animals
AU2017261705B2 (en) * 2016-05-10 2024-04-18 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
US10632185B2 (en) 2016-07-08 2020-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/zika viruses and methods of use
CN108795920B (zh) * 2018-06-22 2022-04-08 苏州良辰生物医药科技有限公司 一种胰酶的制备方法
EP4031152A4 (en) * 2019-09-18 2023-10-04 Research Development Foundation METHODS AND PROBIOTIC COMPOSITIONS FOR TREATING METABOLIC DISEASES AND DISORDERS
US20220040291A1 (en) * 2020-08-10 2022-02-10 Timothy S. Moore HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION
WO2022066636A1 (en) * 2020-09-22 2022-03-31 Goldilocks Therapeutics, Inc. Nanoparticles and methods of use thereof
ES2905658B2 (es) * 2020-10-09 2022-09-29 Univ La Laguna Sistema de captación e inactivación de patógenos
CN115381935A (zh) * 2022-07-05 2022-11-25 石河子大学 一种bvdv灭活疫苗及其制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) * 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
GB933711A (en) * 1959-11-12 1963-08-14 Wellcome Found Metazoan endoparasite vaccines
US3932943A (en) * 1970-08-14 1976-01-20 E. I. Du Pont De Nemours And Company Method of preparation of lyophilized biological products
US4181128A (en) * 1975-11-28 1980-01-01 Massachusetts Institute Of Technology Virus inactivation applicator and the like
US4134214A (en) * 1977-08-05 1979-01-16 Merck & Co., Inc. Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55118420A (en) * 1979-03-07 1980-09-11 Sankyo Co Ltd Preparation of improved vaccine for hooping cough
HU183765B (en) * 1981-12-23 1984-05-28 Phylaxia Oltoanyagtermeloe Process for producing lyophilized vaccine against duck hepatitis
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4957735A (en) * 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US4762710A (en) * 1986-06-16 1988-08-09 The United States Of America As Represented By The Department Of Health And Human Services Novel method of preparing toxoid by oxidation and metal ions
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
DK0596032T4 (da) * 1991-07-25 2004-07-26 Idec Pharma Corp Induktion af cytotoksiske T-lymfocytsvar
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5580557A (en) * 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
WO1993017668A1 (en) * 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
CA2433502A1 (en) * 1995-05-04 1996-11-07 Aventis Pasteur Limited Acellular pertussis vaccines and methods of preparation thereof
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
GB9706930D0 (en) * 1997-04-04 1997-05-21 Univ Glasgow Leishmania vaccine
AU4707097A (en) 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
US7098309B2 (en) * 1998-12-23 2006-08-29 Merck & Co., Inc. Recombinant hepatitis B surface antigen
US20040037891A1 (en) 1999-10-04 2004-02-26 Karagoezian Hampar L. Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US6645180B1 (en) * 2000-09-15 2003-11-11 Thomas Hatch Single-use syringe
WO2004002521A1 (en) 2002-06-28 2004-01-08 Novozymes A/S Preparation of vaccines
WO2005001059A2 (en) 2003-06-23 2005-01-06 Novasterilis Inc. Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions
US20050051497A1 (en) * 2003-07-31 2005-03-10 Latino Joseph S. Viral inactivation using ozone
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
ES2396719T3 (es) * 2005-06-20 2013-02-25 Dynamiclear Pty Ltd Composición para tratamiento de lesiones en la piel
ES2423663T3 (es) * 2005-08-08 2013-09-23 Oregon Health And Science University Inactivación de patógenos con peróxido de hidrógeno para la producción de vacunas

Also Published As

Publication number Publication date
WO2008039171A2 (en) 2008-04-03
US20130004525A1 (en) 2013-01-03
AU2006347406A1 (en) 2008-04-03
EP1942932B1 (en) 2013-05-08
WO2008039171A3 (en) 2008-06-12
US8124397B2 (en) 2012-02-28
US20140242115A1 (en) 2014-08-28
US20070031451A1 (en) 2007-02-08
ES2423663T3 (es) 2013-09-23
US10143740B2 (en) 2018-12-04
CA2618306A1 (en) 2007-02-08
US8716000B2 (en) 2014-05-06
EP1942932A2 (en) 2008-07-16
CA2618306C (en) 2014-10-21

Similar Documents

Publication Publication Date Title
PL1942932T3 (pl) Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek
EP2297429A4 (en) SOURCE OF PNEUMATIC MECHANICAL POWER
EP2293756A4 (en) EVACUATION MATTRESSES
ZA200709632B (en) Stretch laminates
GB2469781B (en) Vented baby bottle
IL189237A0 (en) Space disinfection
EP2359713A4 (en) TABLE FRAME
EP2135507A4 (en) DISINFECTANT
SI1968631T1 (sl) Cepivo
GB0504436D0 (en) Vaccine
GB0808699D0 (en) Source controlled sram
GB0522765D0 (en) Combination vaccine manufacture
PL2225175T3 (pl) Stabilizowane roztwory nadtlenku wodoru
GB0509371D0 (en) Resuscitators
EP2148354A4 (en) ELECTRON SOURCE
GB0607272D0 (en) Producing hydrogen peroxide
GB0525800D0 (en) Sterilisation
GB0607277D0 (en) Producing hydrogen peroxide
GB0708122D0 (en) Sparse-coded look-up table
AU325117S (en) Birthing frame
GB0510594D0 (en) Resuscitators
GB0525213D0 (en) Vaccine
GB2426708B (en) Two-Part Disinfectant
GB0523291D0 (en) Treatment table
GB0619588D0 (en) Photo-activated disinfection